[血管性肝病中抗凝剂治疗的特殊特征]
Emmanuelle De Raucourt1, Imen Ben Salah1, Juliette Gay1
1Service d'hématologie biologique, hôpital Beaujon, Clichy, France.
La Revue du praticien
|December 30, 2025
概括
抗凝固药物治疗对于血管性肝病 (VLD) 是至关重要的,但由于门高血压和血栓塞缩症而具有挑战性. 早期启动,仔细评估风险和益处,以及患者教育对于管理出血和血栓形成风险至关重要.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 血管医学 血管医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 抗凝剂对于治疗血管性肝病 (VLD) 是必不可少的.
- 使用因门高血压,血小板缺血和肝功能不全而复杂.
- 消化器切除后介质性缺血引起了人们对口服抗凝剂治疗的担忧.
研究的目的:
- 审查抗凝剂治疗在VLD中的作用和挑战.
- 强调早期启动和风险效益评估的重要性.
- 为管理并发症和特定患者群体提供指导.
主要方法:
- 文献综述侧重于VLD中的抗凝剂使用.
- 分析挑战,包括门高血压,血小板缺血和肝功能不全.
- 讨论治疗选择:低分子量肝素 (LMWH),直接口服抗凝剂 (DOAC) 和维生素K对抗剂 (VKA).
主要成果:
- 抗凝剂治疗对于预防血栓扩张和改善VLD的结果至关重要.
- 需要仔细评估出血和血栓形成风险.
- 中度血小板缺血通常不需要修改治疗;严重的病例需要专门的管理.
- 在Budd-Chiari综合征中,肝功能不全可能会重新平衡血静,凝血试验可能不是可靠的指标.
结论:
- 早期的抗凝剂启动对于VLD至关重要.
- 管理需要仔细考虑患者特异性因素,如血小板缺血和肝功能不全.
- 对食道静脉的系统查和患者教育是护理的重要组成部分.
关键词:
血管病变是一种血管病变.相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.0K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.0K
Venous Thrombosis III: Interprofessional Care
254
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
254
Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.6K
Esophageal Varices-II: Clinical Features and Management
334
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
334
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
157
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
157
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
193
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
193


